BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 23696924)

  • 1. Primary central nervous system lymphoma in immunocompetent individuals: a single center experience.
    Aki H; Uzunaslan D; Saygin C; Batur S; Tuzuner N; Kafadar A; Ongoren S; Oz B
    Int J Clin Exp Pathol; 2013; 6(6):1068-75. PubMed ID: 23696924
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Diagnostic delay and outcome in immunocompetent patients with primary central nervous system lymphoma in Spain: a multicentric study.
    Velasco R; Mercadal S; Vidal N; Alañá M; Barceló MI; Ibáñez-Juliá MJ; Bobillo S; Caldú Agud R; García Molina E; Martínez P; Cacabelos P; Muntañola A; García-Catalán G; Sancho JM; Camro I; Lado T; Erro ME; Gómez-Vicente L; Salar A; Caballero AC; Solé-Rodríguez M; Gállego Pérez-Larraya J; Huertas N; Estela J; Barón M; Barbero-Bordallo N; Encuentra M; Dlouhy I; Bruna J; Graus F;
    J Neurooncol; 2020 Jul; 148(3):545-554. PubMed ID: 32524392
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A new prognostic score for disease progression and mortality in patients with newly diagnosed primary CNS lymphoma.
    Liu CJ; Lin SY; Yang CF; Yeh CM; Kuan AS; Wang HY; Tsai CK; Gau JP; Hsiao LT; Chen PM; Liu YC; Hong YC; Ko PS; Liu JH; Lin CH
    Cancer Med; 2020 Mar; 9(6):2134-2145. PubMed ID: 32011103
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evolution of the treatment of primary central nervous system lymphoma in a Regional Cancer Center of South India: Impact of high-dose methotrexate on treatment outcome.
    Rudresha AH; Chaudhuri T; Lakshmaiah KC; Babu G; Lokesh KN; Rajeev LK
    J Cancer Res Ther; 2020; 16(1):13-17. PubMed ID: 32362603
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Endothelial hyperplasia and endothelial galectin-3 expression are prognostic factors in primary central nervous system lymphomas.
    D'Haene N; Catteau X; Maris C; Martin B; Salmon I; Decaestecker C
    Br J Haematol; 2008 Feb; 140(4):402-10. PubMed ID: 18081894
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinicopathological analysis and specific discriminating markers of interleukin detection in cerebrospinal fluid with primary central nervous system lymphoma: results from a retrospective study.
    Li J; Tang X; Luo X; Liu L; Li D; Yang L
    Ann Hematol; 2023 Aug; 102(8):2153-2163. PubMed ID: 37289220
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Primary central nervous system lymphoma: clinical experience in a neurological center].
    Gomez-Figueroa E; Peiro-Osuna RP; Reyes-Moreno I; Hernandez-Hernandez A; Gutierrez-Aceves A; Santos-Zambrano J; Guerrero-Juarez V; Lopez-Martinez M; Castro-Martinez E; Gonzalez-Aguilar A
    Rev Neurol; 2019 Jan; 68(2):59-65. PubMed ID: 30638255
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Primary central nervous system lymphoma: immunohistochemical profile and prognostic significance.
    Raoux D; Duband S; Forest F; Trombert B; Chambonnière ML; Dumollard JM; Khaddage A; Gentil-Perret A; Péoc'h M
    Neuropathology; 2010 Jun; 30(3):232-40. PubMed ID: 19925562
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Balancing relapses versus cognitive impairment in primary central nervous system lymphoma: a single-center experience.
    Chanswangphuwana C; Rojnuckarin P; Cherdchoo N; Raiyawa T; Uaprasert N
    Hematology; 2018 Aug; 23(7):385-390. PubMed ID: 29256330
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Primary central nervous system lymphoma.
    Batchelor TT
    Hematology Am Soc Hematol Educ Program; 2016 Dec; 2016(1):379-385. PubMed ID: 27913504
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Cleveland Clinic experience with primary central nervous system lymphoma.
    Xie H; Ahluwalia MS; Peereboom DM
    Am J Clin Oncol; 2015 Apr; 38(2):140-6. PubMed ID: 23608829
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Utility of post-therapy brain surveillance imaging in the detection of primary central nervous system lymphoma relapse.
    Fossard G; Ferlay C; Nicolas-Virelizier E; Rey P; Ducray F; Jouanneau E; Faurie P; Belhabri A; Sunyack MP; Chassagne-Clément C; Thiesse P; Sebban C; Biron P; Blay JY; Ghesquières H
    Eur J Cancer; 2017 Feb; 72():12-19. PubMed ID: 28012348
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Clinical features and treatment outcomes in primary central nervous system lymphoma: a descriptive analysis of 62 patients].
    Ge Y; Lin XT; Luo DL; Zhang F; Xu J; Li Z; Liu YH
    Zhonghua Bing Li Xue Za Zhi; 2019 Nov; 48(11):861-866. PubMed ID: 31775435
    [No Abstract]   [Full Text] [Related]  

  • 14. Primary central nervous system diffuse large B-cell lymphoma has poorer immune cell infiltration and prognosis than its peripheral counterpart.
    Chang C; Lin CH; Cheng AL; Medeiros LJ; Chang KC
    Histopathology; 2015 Nov; 67(5):625-35. PubMed ID: 25829022
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A new prognostic model using absolute lymphocyte count in patients with primary central nervous system lymphoma.
    Jang JE; Kim YR; Kim SJ; Cho H; Chung H; Lee JY; Park H; Kim Y; Cheong JW; Min YH; Kim JS
    Eur J Cancer; 2016 Apr; 57():127-35. PubMed ID: 26918738
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of treatment variability on survival in immuno-competent and immuno-compromised patients with primary central nervous lymphoma.
    Karmali R; Nabhan C; Petrich AM; Raizer J; Peace D; Lukas R; Gordon LI; Basu S; Chukkapalli V; Venugopal P
    Br J Haematol; 2017 Apr; 177(1):72-79. PubMed ID: 28211579
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Primary central nervous system lymphoma involving the hypothalamic-pituitary axis: a case series and pooled analysis.
    Shin DW; Kim JH; Kim YH; Cho YH; Hong SH
    J Neurooncol; 2020 Apr; 147(2):339-349. PubMed ID: 32221784
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combined tumor-associated macrophages biomarker predicting extremely poor outcome of patients with primary central nervous system lymphoma.
    Sun X; Wang C; Chen C; Huang J; Wu X; Wang Y; He X; Cao J; Jiang W; Sun P; Li Z
    Hematol Oncol; 2021 Dec; 39(5):625-638. PubMed ID: 34543472
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of front line relative dose intensity for methotrexate and comorbidities in immunocompetent elderly patients with primary central nervous system lymphoma.
    Farhi J; Laribi K; Orvain C; Hamel JF; Mercier M; Sutra Del Galy A; Clavert A; Rousselet MC; Tanguy-Schmidt A; Hunault-Berger M; Moles-Moreau MP
    Ann Hematol; 2018 Dec; 97(12):2391-2401. PubMed ID: 30091022
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Central nervous system recurrence of systemic lymphoma in the era of stem cell transplantation--an International Primary Central Nervous System Lymphoma Study Group project.
    Bromberg JE; Doorduijn JK; Illerhaus G; Jahnke K; Korfel A; Fischer L; Fritsch K; Kuittinen O; Issa S; van Montfort C; van den Bent MJ
    Haematologica; 2013 May; 98(5):808-13. PubMed ID: 23144196
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.